Stockscreener 앱 받기
16.17
11.59%
1.68
Cadrenal Therapeutics Inc 주식(CVKD)의 최신 뉴스
Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility - The Eastern Progress Online
CVKDCadrenal Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Cadrenal Therapeutics to Showcase Novel Anticoagulant Tecarfarin at J.P. Morgan Healthcare Conference - StockTitan
(CVKD) Trading Report - Stock Traders Daily
What is Zacks Small Cap’s Estimate for CVKD FY2024 Earnings? - Defense World
CVKD: Recent Financings Raise $9.8 Million… - MSN
Kairos Pharma approved to dual list on Upstream - MSN
Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook - StockTitan
(CVKD) Technical Data - Stock Traders Daily
ARMISTICE CAPITAL, LLC Acquires New Stake in Cadrenal Therapeuti - GuruFocus.com
Cadrenal's Tecarfarin Shows Promise for LVAD Patients in Key Medical Congress Data | CVKD Stock News - StockTitan
Cadrenal shares gain; analyst highlights Buy rating and key LVAD trial advancements - Investing.com Canada
Cadrenal Therapeutics Provides Third-Quarter Corporate Update - Defense World
(CVKD) Long Term Investment Analysis - Stock Traders Daily
Cadrenal Therapeutics Advances Tecarfarin Development - TipRanks
Cadrenal Therapeutics Raises $9.8M, Advances Unique Anticoagulant Drug Development | CVKD Stock News - StockTitan
Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds - StockTitan
Here's Why We're Watching Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn Situation - Simply Wall St
We're Keeping An Eye On Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn Rate - Yahoo Finance
(CVKD) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Cadrenal Therapeutics secures $5.1 million in share sale - Investing.com
Cadrenal Therapeutics Raises $5.1 Million for Tecarfarin - TipRanks
CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM - PR Newswire
Short Interest in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Drops By 7.2% - MarketBeat
Renaissance Technologies LLC Reduces Stock Position in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) - MarketBeat
Long Term Trading Analysis for (CVKD) - Stock Traders Daily
Jacksonville stocks rise as market hits record highs - Jacksonville Daily Record
Short Interest in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Rises By 22.8% - MarketBeat
Cadrenal Therapeutics Inc (CVKD-Q) QuotePress Release - The Globe and Mail
Where are the Opportunities in (CVKD) - Stock Traders Daily
Cadrenal Therapeutics Unveils Phase 3 Trials and Market Strategy - TipRanks
Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference - Kilgore News Herald
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Forecasted to Earn Q3 2024 Earnings of ($2.18) Per Share - MarketBeat
Applied Therapeutics (NASDAQ:APLT) Trading Down 4.1% - Defense World
WATCH LIVE: Fed Chair Jerome Powell speaks after a 50bp interest rate cut - Investing.com
Cancer Biotech Nuvalent’s Stock Jumps on Positive Data - MSN
Cadrenal Therapeutics (CVKD) Stock Rallies In After-Market Trading Ahead Of Regulatory Meeting - Stocks Telegraph
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Update - MarketBeat
Eli Lilly invests $1.8B to boost manufacturing footprint in Ireland - MSN
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing - Yahoo Finance
Cadrenal Therapeutics regains Nasdaq compliance - Investing.com India
Cadrenal gears up for FDA talks on heart drug trial - Investing.com India
Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients - PR Newswire
Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients - PR Newswire
Upcoming Stock Splits This Week (August 19 to August 23) – Stay InvestingTHE BHARAT EXPRESS NEWS - The Bharat Express News
Upcoming Stock Splits This Week (August 19 to August 23) – Stay Invested - MSN
2.88%
2.65%
자본화:
|
볼륨(24시간):